STOCK TITAN

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
ArriVent BioPharma (Nasdaq: AVBP) has announced a virtual investor event scheduled for June 23, 2025 at 8:00 am ET. The webinar will focus on discussing the clinical program for firmonertinib, their investigational treatment for EGFR PACC mutant non-small cell lung cancer (NSCLC). The event aims to provide investors with insights into the development path and strategy for this therapeutic candidate. ArriVent, a clinical-stage biopharmaceutical company, is focused on accelerating the global development of innovative therapeutics.
ArriVent BioPharma (Nasdaq: AVBP) ha annunciato un evento virtuale per investitori programmato per il 23 giugno 2025 alle 8:00 ET. Il webinar sarà dedicato alla discussione del programma clinico di firmonertinib, il loro trattamento sperimentale per il cancro polmonare non a piccole cellule (NSCLC) con mutazione EGFR PACC. L'evento ha l'obiettivo di fornire agli investitori approfondimenti sul percorso di sviluppo e sulla strategia di questo candidato terapeutico. ArriVent, azienda biofarmaceutica in fase clinica, è focalizzata sull'accelerazione dello sviluppo globale di terapie innovative.
ArriVent BioPharma (Nasdaq: AVBP) ha anunciado un evento virtual para inversores programado para el 23 de junio de 2025 a las 8:00 am ET. El seminario web se centrará en discutir el programa clínico de firmonertinib, su tratamiento en investigación para el cáncer de pulmón no microcítico (NSCLC) con mutación EGFR PACC. El evento tiene como objetivo brindar a los inversores información sobre la trayectoria de desarrollo y la estrategia para este candidato terapéutico. ArriVent, una compañía biofarmacéutica en etapa clínica, se enfoca en acelerar el desarrollo global de terapias innovadoras.
ArriVent BioPharma(Nasdaq: AVBP)는 2025년 6월 23일 오전 8시(동부시간)에 가상 투자자 이벤트를 개최할 예정이라고 발표했습니다. 이번 웨비나는 EGFR PACC 돌연변이 비소세포폐암(NSCLC) 치료를 위한 임상 시험 중인 약물인 firmonertinib의 임상 프로그램에 대해 논의하는 데 중점을 둘 예정입니다. 이 행사는 투자자들에게 이 치료 후보물질의 개발 경로와 전략에 대한 통찰을 제공하는 것을 목표로 합니다. 임상 단계의 바이오제약 회사인 ArriVent는 혁신적인 치료제의 글로벌 개발 가속화에 주력하고 있습니다.
ArriVent BioPharma (Nasdaq : AVBP) a annoncé un événement virtuel pour les investisseurs prévu le 23 juin 2025 à 8h00 ET. Le webinaire portera sur le programme clinique de firmonertinib, leur traitement expérimental pour le cancer du poumon non à petites cellules (NSCLC) mutant EGFR PACC. L'événement vise à fournir aux investisseurs des informations sur la voie de développement et la stratégie pour ce candidat thérapeutique. ArriVent, une société biopharmaceutique en phase clinique, se concentre sur l'accélération du développement mondial de traitements innovants.
ArriVent BioPharma (Nasdaq: AVBP) hat eine virtuelle Investorenveranstaltung für den 23. Juni 2025 um 8:00 Uhr ET angekündigt. Das Webinar wird sich auf das klinische Programm für Firmonertinib konzentrieren, ihre experimentelle Behandlung für EGFR PACC-mutiertes nicht-kleinzelliges Lungenkarzinom (NSCLC). Ziel der Veranstaltung ist es, Investoren Einblicke in den Entwicklungsweg und die Strategie für diesen therapeutischen Kandidaten zu geben. ArriVent, ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich darauf, die globale Entwicklung innovativer Therapeutika zu beschleunigen.
Positive
  • None.
Negative
  • None.

Virtual webinar on June 23, 2025 at 8:00 am ET

NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) on June 23, 2025 at 8:00 am ET. To register for the event, please click here.

About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.

About Firmonertinib
Firmonertinib (formerly furmonertinib) is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. In March 2021, firmonertinib was approved in China for first-line advanced non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutations and for patients with previously treated locally advanced or metastatic NSCLC with EGFR T790M mutation, otherwise known as EGFR classical mutations.

Firmonertinib was granted U.S. Food and Drug Administration Breakthrough Therapy Designation for the treatment of patients with previously untreated locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. Firmonertinib was also granted U.S. Food and Drug Administration Orphan Drug Designation for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations or human epidermal growth factor receptor 2 (HER2) mutations or HER4 mutations.

Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase 1b study, which includes a cohort evaluating firmonertinib in patients with EGFR PACC mutations (FURTHER; NCT05364073). In addition, firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations, in partnership with Beijing InnoCare Pharma Tech Co., Ltd.

About EGFR mutant NSCLC
Globally, lung cancer is the leading cause of cancer-related deaths among men and women. NSCLC is the predominant subtype of lung cancer, accounting for approximately 85% of all cases. Mutational activation of the EGFR is a frequent and early event in the development of NSCLC. EGFR mutations are divided into classical and uncommon. EGFR exon 20 insertion mutations are a group of uncommon EGFR mutations and constitute approximately 9% of all EGFR mutations. PACC mutations are another group of uncommon EGFR mutations and represent approximately 12% of all EGFR mutations. Patients with NSCLC whose tumors harbor uncommon EGFR mutations have significantly lower life expectancy with available therapies and represent an area of unmet medical need.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, activity of firmonertinib compared to available therapies, anticipated clinical milestones, including the top-line pivotal global Phase 3 data for firmonertinib in previously untreated NSCLC patients whose tumors contain EGFR exon 20 insertion mutations, expansion of firmonertinib into a pivotal trial for 1L EGFR PACC mutant NSCLC and the timing of the first patient enrolled in such study, participation in the global Phase 3 registrational study of firmonertinib in adjuvant uncommon mutant NSCLC, anticipated IND filings for ADC candidates, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on March 3, 2025 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com


FAQ

When is ArriVent's (AVBP) investor event for firmonertinib?

ArriVent's virtual investor event is scheduled for June 23, 2025 at 8:00 am ET.

What is the focus of ArriVent's (AVBP) upcoming investor webinar?

The webinar will discuss the firmonertinib clinical program for treating EGFR PACC mutant non-small cell lung cancer (NSCLC).

What type of company is ArriVent BioPharma (AVBP)?

ArriVent is a clinical-stage biopharmaceutical company focused on accelerating the global development of innovative therapeutics.

What cancer type is ArriVent's firmonertinib targeting?

Firmonertinib is being developed for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC).
Arrivent Biopharma Inc

NASDAQ:AVBP

AVBP Rankings

AVBP Latest News

AVBP Stock Data

808.44M
27.85M
9.72%
84.55%
10.97%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEWTOWN SQUARE